Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis - Wikidata - wikimedia - TriplyDB

Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis

Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis

http://www.wikidata.org/entity/Q35977704

about

My approach to the treatment of scleroderma Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis Mycophenolate mofetil for scleroderma-related interstitial lung disease: A real world experience.Effect of mycophenolate mofetil on progression of interstitial fibrosis and tubular atrophy after kidney transplantation: a retrospective study Scleroderma lung disease Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis Latest advances in connective tissue disorders.Molecular biomarkers in interstitial lung diseases.Recent advances in connective tissue disease related interstitial lung disease.Interstitial lung disease in systemic sclerosis: current and future treatment.Pharmacogenetics and interstitial lung disease.Dramatic improvement of anti-SS-A/Ro-associated interstitial lung disease after immunosuppressive treatment.Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis [Established medications : new areas of application].Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study.Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease.Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.

P2860

Q24618843-77CA9F57-406E-4468-A3EC-D3CF0B98E266 Q26775753-11520727-C2B5-4549-B8DA-FB59D1B09370 Q33602730-98FE51F3-A707-4963-8C7B-381278D9AAE3 Q33727800-51018AAE-5413-48A5-8E01-8C21CBBDBACE Q33879559-A3B9F4CC-DAF7-4D60-BC62-8BC4F7224767 Q33919119-7D14A310-E64E-4BA7-8815-991A8030D3F8 Q35560664-1678813B-199F-4568-BDCB-7ED4A9C94F47 Q36960060-C29EF215-D9B7-44E5-BFF8-715FB7453B7E Q37058776-F2647959-A14F-4FB9-B50C-ECA372B292DC Q38220769-E5F60651-A364-4D9F-9342-CD035F97D60C Q38678939-8CE36542-EE90-41BB-BFDF-6AADD9DDC88A Q38773637-14555CA2-AA44-43F8-9D6E-88110164F52D Q38851479-3DCA0E1F-F256-4C07-A1B8-69D2DD952482 Q39883870-C7DA4F7B-5519-4E7A-866A-A3110267B7DA Q41513645-AF92669E-55CD-4003-B1BE-562A47546F81 Q44480906-BB867D7F-C726-467E-9270-2BD3980728C7 Q45167705-67FDD32F-57C9-406D-8F32-5A299F196354 Q46758099-39E08F06-AD8C-4BBF-AEAE-1D3274C1F5CE Q49166002-DF56E3CD-7BD5-4AF5-A987-708A401738A6

P2860

Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis

http://www.wikidata.org/entity/Q35977704

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Effect and safety of mycopheno ...... lung disease: a meta-analysis

@ast

Effect and safety of mycopheno ...... lung disease: a meta-analysis

@en

type

label

Effect and safety of mycopheno ...... lung disease: a meta-analysis

@ast

Effect and safety of mycopheno ...... lung disease: a meta-analysis

@en

prefLabel

Effect and safety of mycopheno ...... lung disease: a meta-analysis

@ast

Effect and safety of mycopheno ...... lung disease: a meta-analysis

@en

P1433

Q35977704-D837B932-8E55-46E1-81AD-ED3D942AEABD

P1476

Q35977704-794301A7-A0CD-48DC-9595-7E9309E17902

P2093

Q35977704-0B32E1E0-4E01-4E69-BB77-531CF1C25C0F

Q35977704-25830642-1FF7-4FCA-90DD-42076343AF15

Q35977704-38AAC86D-DE64-4172-9A41-E837B49F55B2

Q35977704-4B9B0A82-7381-44F9-8073-DEC8F80BB5CE

Q35977704-8693BA98-8237-4F88-B280-B9091F24805E

Q35977704-92F097F5-EB5E-4D6A-8860-4B58CF19D016

Q35977704-BA0D08E2-FD8B-4EAE-88E6-E03B3558E1DD

Q35977704-E76A9AB3-0EAD-4886-A9A1-3B7BE45E9BC6

P2860

Q35977704-27AE63E7-7622-48DE-86FB-E8DA8F61FC8F

Q35977704-29B064CE-3053-404C-BDCE-3B595F7A199F

Q35977704-2F87FE2C-B761-45AD-BB09-D6EB74FB9417

Q35977704-3E0D03BE-903F-4D49-932E-45E361801C2E

Q35977704-45F61707-8C32-4A3F-95E4-9CE1C37132AB

Q35977704-51CA0CDC-9EFC-4A6B-8B4D-0AA7FDAADCCC

Q35977704-559FA89E-E866-49DA-86C4-7D154EB89260

Q35977704-5640F9BD-893F-4550-8EAF-2343AF8A18F0

Q35977704-57B7A335-B654-4964-8335-B5D33676AC67

Q35977704-5A62E263-DB17-4FB4-A452-68C4AC987C85

P304

Q35977704-D355F7E0-D4D6-41BD-9CB2-A966C8A0E6CF

P31

Q35977704-13D4D1B9-7EA7-4737-8B39-8CCB8094F12D

P356

Q35977704-E92401FA-FF08-4433-A2D7-B1BED5144780

P478

Q35977704-5C8C9F22-3257-4C1B-BB84-8C19EF1F0EF2

P50

Q35977704-6A0587C0-34E8-4725-A6EE-5792A82C06BB

P577

Q35977704-6BC85ADC-7B91-449F-9182-0E78004F37B5

P5875

Q35977704-DD8BD2B0-4A4B-446E-8926-14F814E2E00A

P698

Q35977704-8BC44C35-E5AD-4096-8498-3B11703319AE

P932

Q35977704-8DC4D553-4343-42F1-9A08-527B330F2684

P356

P1433

Pulmonary Medicine

P1476

Effect and safety of mycopheno ...... lung disease: a meta-analysis

@en

P2093

Anastasia Oikonomou

http://www.w3.org/2001/XMLSchema#string

Andreas Koulelidis

http://www.w3.org/2001/XMLSchema#string

Argyris Tzouvelekis

http://www.w3.org/2001/XMLSchema#string

Demosthenes Bouros

http://www.w3.org/2001/XMLSchema#string

Evangelos Bouros

http://www.w3.org/2001/XMLSchema#string

George Zacharis

http://www.w3.org/2001/XMLSchema#string

Nikolaos Galanopoulos

http://www.w3.org/2001/XMLSchema#string

Paschalis Ntolios

http://www.w3.org/2001/XMLSchema#string

P2860

Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease.

Mycophenolate mofetil and its mechanisms of action.

Cyclophosphamide versus placebo in scleroderma lung disease.

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.

Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society.

High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned.

Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database

Genetics of lupus nephritis.

Mechanisms of action of mycophenolate mofetil.

Clinical trials in systemic sclerosis: lessons learned and outcomes.

P304

143637

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/143637

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225087393

http://www.w3.org/2001/XMLSchema#string

P698

22655194

http://www.w3.org/2001/XMLSchema#string

P932

3357562

http://www.w3.org/2001/XMLSchema#string